卵巢颗粒细胞瘤放疗经验:来自GCT幸存者姐妹会的洞察
通过跨国封闭Facebook群组GCT幸存者姐妹会(成员n=1800)开展调查,分析1017份问卷(96%为成人型GCT),受访者主要来自美国(62%)、2015年后确诊(67%)、44%有复发疾病。12%受访者报告放疗(9%已接受、3%计划中),多用于复发疾病(23%)。开放性问题归纳出五个主题:四个积极(有效、比其他治疗更轻松、让我重获生活、给予希望)和一个反映严重副作用的消极主题。
要点
- 1017份问卷中12%报告放疗(9%已接受、3%计划中),多用于复发疾病(23%)。
- 复发疾病放疗比例因国家而异:加拿大12%、英国14%、欧盟14%、澳大利亚/新西兰36%、美国25%(p=.019)。
- 开放性问题归纳五个主题:四个积极(有效、更轻松、重获生活、给予希望)和一个反映严重副作用的消极主题。
核心结论
- GCT放疗不常见,反映了不同国家的治疗推荐差异。
- 由于女性多报告积极体验,需要开展研究以建立关于GCT管理中放疗最佳时机和顺序的证据基础。
研究设计与样本
- 通过跨国封闭Facebook群组GCT幸存者姐妹会(成员n=1800)开展调查,邀请≥18岁成员完成问卷,评估诊断与治疗、放疗经历及放疗影响,并设两道开放性问题了解放疗体验。
- 共分析1017份问卷(96%为成人型GCT),受访者主要来自美国(62%)、2015年后确诊(67%)、44%有复发疾病。
- 采用逻辑回归分析与放疗相关的因素。
主要发现
- 12%受访者报告放疗(9%已接受、3%计划中),多用于复发疾病(23%)。
- 单因素分析中,复发疾病放疗比例因国家而异(p=.019):加拿大12%、英国14%、欧盟14%、澳大利亚/新西兰36%、美国25%。
- 单因素分析中,复发疾病放疗与年龄(p=.02;≥50岁26%、≤50岁17%)、接受化疗(p=.019)和激素治疗(p<.001)相关。
- 开放性问题分析归纳五个主题:四个积极主题(有效、比其他治疗更轻松、让我重获生活、给予希望)和一个反映严重副作用的消极主题。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Optimal treatment of ovarian Granulosa Cell Tumors (GCT) is uncertain due to a lack of evidence from randomized trials. The role of radiotherapy is unclear and recommendations differ between countries. Through an ongoing collaboration with the multinational closed GCT Survivor Sisters (GCT-SS) Facebook™ group (membership n = 1800) we developed a survey to understand members' experiences of radiotherapy. METHODS: GCT-SS members (≥18+ years) were invited to complete the survey assessing i) diagnosis and treatment, ii) radiotherapy experiences and iii) radiotherapy impact. Two questions allowed free-text responses about radiotherapy experiences. Country of residence was assessed (USA, Canada, United Kingdom (UK), European Union (EU), Australia/New Zealand (Aus/NZ); Other). Logistic regression examined factors associated with radiotherapy. RESULT: Surveys from 1017 members (96 % Adult-GCT) are analysed. Respondents were mostly from the USA (62 %), diagnosed post-2015 (67 %), and 44 % had recurrent disease. Overall, 12 % of respondents reported radiotherapy (9 % received, 3 % planned), mostly for recurrent (23 %) disease. In univariate analyses, radiotherapy for recurrent disease differed by country (p = .019) (Canada (12 %), UK (14 %), EU (14 %), Aus/NZ (36 %), USA (25 %)); age (p = .02) (≥50 (26 %) ≤50 (17 %)) having chemotherapy (p = .019) and hormonal therapy (p < .001). Analyses of open-ended questions found five themes: four positive (it worked; easier than other treatments, gave me back my life, gives hope) and one negative reflecting severe side-effects. CONCLUSIONS: Radiotherapy for GCT is not common and reflects treatment recommendations in different countries. As women mostly report positive experiences, studies are needed to develop an evidence-base regarding its optimal timing and sequencing in managing GCT.
引用
- White VM, Langdale LM, Eroh KD, et al. Experiences of radiotherapy for treatment of Granulosa Cell Tumor of the ovary: insights from the GCT-survivor sisters. Gynecol Oncol. 2025. PMID: 41175448. doi:10.1016/j.ygyno.2025.10.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。